| 000 | 01308 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250518013238.0 | ||
| 264 | 0 | _c20190528 | |
| 008 | 201905s 0 0 hun d | ||
| 022 | _a0030-6002 | ||
| 024 | 7 |
_a10.1556/650.2018.31214 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJermendy, György | |
| 245 | 0 | 0 |
_a[Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective]. _h[electronic resource] |
| 260 |
_bOrvosi hetilap _cDec 2018 |
||
| 300 |
_a2122-2128 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHungary |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin Glargine _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin, Long-Acting _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReimbursement Mechanisms _xstatistics & numerical data |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKovács, Gábor | |
| 773 | 0 |
_tOrvosi hetilap _gvol. 159 _gno. 50 _gp. 2122-2128 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1556/650.2018.31214 _zAvailable from publisher's website |
| 999 |
_c29158256 _d29158256 |
||